BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Covington
Queensland Health
US Department of Justice
Moodys
Merck
Accenture
Medtronic
Boehringer Ingelheim
Dow

Generated: January 22, 2018

DrugPatentWatch Database Preview

Bristol Myers Squibb Company Profile

« Back to Dashboard

What is the competitive landscape for BRISTOL MYERS SQUIBB, and when can generic versions of BRISTOL MYERS SQUIBB drugs launch?

BRISTOL MYERS SQUIBB has seventy-seven approved drugs.

There are eighteen US patents protecting BRISTOL MYERS SQUIBB drugs and there have been three Paragraph IV challenges on BRISTOL MYERS SQUIBB drugs in the past three years.

There are four hundred and sixty-three patent family members on BRISTOL MYERS SQUIBB drugs in fifty-eight countries and one hundred and seventy-four supplementary protection certificates in fifteen countries.

Summary for Bristol Myers Squibb
International Patents:463
US Patents:18
Tradenames:66
Ingredients:58
NDAs:77

Drugs and US Patents for Bristol Myers Squibb

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bristol Myers Squibb PRAVACHOL pravastatin sodium TABLET;ORAL 019898-003 Oct 31, 1991 AB RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Bristol Myers Squibb SPRYCEL dasatinib TABLET;ORAL 021986-002 Jun 28, 2006 AB RX Yes No ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Bristol Myers Squibb PRAVIGARD PAC (COPACKAGED) aspirin; pravastatin sodium TABLET, TABLET, TABLET;ORAL 021387-002 Jun 24, 2003 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Bristol Myers Squibb BARACLUDE entecavir TABLET;ORAL 021797-002 Mar 29, 2005 AB RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Bristol Myers Squibb SPRYCEL dasatinib TABLET;ORAL 021986-005 Oct 28, 2010 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Bristol Myers Squibb CLINDAMYCIN PHOSPHATE clindamycin phosphate INJECTABLE;INJECTION 062908-001 Feb 1, 1989 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Bristol Myers Squibb NARCAN naloxone hydrochloride INJECTABLE;INJECTION 071311-001 Jul 28, 1988 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Bristol Myers Squibb BARACLUDE entecavir TABLET;ORAL 021797-001 Mar 29, 2005 AB RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Bristol Myers Squibb COUMADIN warfarin sodium TABLET;ORAL 009218-013 Approved Prior to Jan 1, 1982 AB RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Bristol Myers Squibb SERZONE nefazodone hydrochloride TABLET;ORAL 020152-003 Dec 22, 1994 DISCN Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Bristol Myers Squibb

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bristol Myers Squibb SUSTIVA efavirenz CAPSULE;ORAL 020972-002 Sep 17, 1998 ➤ Subscribe ➤ Subscribe
Bristol Myers Squibb PRAVACHOL pravastatin sodium TABLET;ORAL 019898-004 Mar 22, 1993 ➤ Subscribe ➤ Subscribe
Bristol Myers Squibb MONOPRIL-HCT fosinopril sodium; hydrochlorothiazide TABLET;ORAL 020286-001 Nov 30, 1994 ➤ Subscribe ➤ Subscribe
Bristol Myers Squibb SERZONE nefazodone hydrochloride TABLET;ORAL 020152-005 Dec 22, 1994 ➤ Subscribe ➤ Subscribe
Bristol Myers Squibb MONOPRIL fosinopril sodium TABLET;ORAL 019915-003 May 16, 1991 ➤ Subscribe ➤ Subscribe
Bristol Myers Squibb PRAVIGARD PAC (COPACKAGED) aspirin; pravastatin sodium TABLET, TABLET, TABLET;ORAL 021387-005 Jun 24, 2003 ➤ Subscribe ➤ Subscribe
Bristol Myers Squibb REYATAZ atazanavir sulfate CAPSULE;ORAL 021567-003 Jun 20, 2003 ➤ Subscribe ➤ Subscribe
Bristol Myers Squibb VIDEX didanosine FOR SOLUTION;ORAL 020155-006 Oct 9, 1991 ➤ Subscribe ➤ Subscribe
Bristol Myers Squibb ETOPOPHOS PRESERVATIVE FREE etoposide phosphate INJECTABLE;INJECTION 020906-002 Feb 27, 1998 ➤ Subscribe ➤ Subscribe
Bristol Myers Squibb ZERIT XR stavudine CAPSULE, EXTENDED RELEASE;ORAL 021453-004 Dec 31, 2002 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for BRISTOL MYERS SQUIBB drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Tablets 2.5 mg and 5 mg ➤ Subscribe 12/28/2016
➤ Subscribe Capsules 50 mg, 100 mg and 200 mg ➤ Subscribe 11/3/2016
➤ Subscribe Nasal Spray 4 mg/spray ➤ Subscribe 7/15/2016
➤ Subscribe Tablets 80 mg and 140 mg ➤ Subscribe 6/17/2011
➤ Subscribe Tablets 80 mg and 140 mg ➤ Subscribe 6/16/2011
➤ Subscribe Tablets 20 mg, 50 mg, 70 mg and 100 mg ➤ Subscribe 6/28/2010
➤ Subscribe Tablets 0.5 mg and 1 mg ➤ Subscribe 6/14/2010
➤ Subscribe Capsules 100 mg and 150 mg ➤ Subscribe 3/19/2010
➤ Subscribe Capsules 200 mg ➤ Subscribe 2/16/2010
➤ Subscribe Capsules 300 mg ➤ Subscribe 7/20/2009
➤ Subscribe Tablets 600 mg ➤ Subscribe 4/9/2009
➤ Subscribe Tablets 30 mg ➤ Subscribe 6/1/2005
➤ Subscribe Delayed-release Capsules 200 mg, 250 mg and 400 mg ➤ Subscribe 6/1/2004

Non-Orange Book US Patents for Bristol Myers Squibb

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,960,411 Lactam-containing compounds and derivatives thereof as factor Xa inhibitors ➤ Subscribe
9,382,219 Cyclic protein tyrosine kinase inhibitors ➤ Subscribe
6,995,172 Lactam-containing compounds and derivatives thereof as factor Xa inhibitors ➤ Subscribe
8,716,323 Cyclic protein tyrosine kinase inhibitors ➤ Subscribe
6,110,946 Antivirally active heterocyclic azahexane derivatives ➤ Subscribe
7,691,846 Lactam-containing compounds and derivatives thereof as factor Xa inhibitors ➤ Subscribe
6,989,391 Lactam-containing compounds and derivatives thereof as factor Xa inhibitors ➤ Subscribe
7,371,761 Lactam-containing compounds and derivatives thereof as factor Xa inhibitors ➤ Subscribe
6,979,694 Cyclic protein tyrosine kinase inhibitors ➤ Subscribe
7,005,435 Lactam-containing compounds and derivatives thereof as factor Xa inhibitors ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for Bristol Myers Squibb Drugs

Supplementary Protection Certificates for Bristol Myers Squibb Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0001 France ➤ Subscribe PRODUCT NAME: ETHINYLESTRADIOL BETADEX CLATHRATE; NAT. REGISTRATION NO/DATE: NL 32343 20060710; FIRST REGISTRATION: NL - RVG 31781 20050804
2107069/02 Switzerland ➤ Subscribe PRODUCT NAME: INSULIN DEGLUDEC + INSULIN ASPART; REGISTRATION NO/DATE: SWISSMEDIC 62648 12.09.2013
2004005,C0792290 Lithuania ➤ Subscribe PRODUCT NAME: INSULIN DETEMIR; REGISTRATION NO/DATE: EU/1/04/278/001, EU/1/04/278/002, EU/1/04/278/003, EU/1/04/278/004, EU/1/04/278/005, EU/1/04/278/006, EU/1/04/278/007, EU/1/04/278/008, EU/1/04/278/00 20040601
90004-8 Sweden ➤ Subscribe PRODUCT NAME: DASATINIB OCH FARMACEUTISKT GODTAGBARA SALTER DAERAV; REG. NO/DATE: EU/1/06/363/001 20061120
2107069/01 Switzerland ➤ Subscribe PRODUCT NAME: INSULIN DEGLUDEC; REGISTRATION NO/DATE: SWISSMEDIC 62563 12.03.2013
2016 00016 Denmark ➤ Subscribe PRODUCT NAME: LEVONORGESTREL OG ETHINYLOESTRADIOL; NAT. REG. NO/DATE: 56336 20151105; FIRST REG. NO/DATE: SK 17/0017/15-S 20150211
1214076/01 Switzerland ➤ Subscribe PRODUCT NAME: DROSPIRENONE + ETHINYLESTRADIOL; REGISTRATION NUMBER/DATE: SWISSMEDIC 57946 13.06.2008
00021 Netherlands ➤ Subscribe PRODUCT NAME: INSULINE ASPART EN GEKRISTALLISEERD PROTAMINE-INSULINE ASPART; NAT. REGISTRATION NO/DATE: EU/1/00/142/001 20000801; FIRST REGISTRATION: 55414015541502 2000230623
13/34 Ireland ➤ Subscribe PRODUCT: INSULIN DEGLUDEC IN ALL ITS FORMS AS THEY ARE PROTECTED BY THE BASIC PATENTS; REGISTRATION NO/DATE: IRELAND EU/1/12/807-001, 004, 005, 007-009, 012, 013 AND 015 / 21/01/2013
77; 5006-2008 Slovakia ➤ Subscribe PRODUCT NAME: SITAGLIPTIN A METFORMIN; REGISTRATION NO/DATE: EU/1/08/455/001-014 20080716
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Dow
Chubb
Medtronic
QuintilesIMS
Baxter
UBS
McKinsey
Julphar
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot